Biomarker ID | 255 |
PMID | 18428198 |
Year | 2008 |
Biomarker | C-reactive protein (CRP) |
Biomarker Basis | Concentration Based (ng/ml) |
Biomolecule | Protein |
Source | Plasma |
Subjects | Humans |
Regulation | Increased in Overall Survival |
Odds Ratio/Hazard Ratio/Relative Risk | OR: 0.741 (95% CI: 0.596-0.920) |
Effect on Pathways | Pathways Include:-Vitamin B12 metabolism,Selenium pathway, Folate metabolism,Interleukin-6 signaling pathway,Complement cascade |
Experiment | PSA Decline Vs No PSA decline |
Type of Biomarker | Prognostic |
Cohort | 250 patients were considered for this placebo control study, out of which 160 blood plasma samples were used for analysis. (64%) |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p=0.0068 |
Method Used | sandwich immunoassay |
Clinical | Yes |
Remarks | Using Cox Regression Analysis. PSA decline was defined as a ≥50% reduction that was confirmed ≥28 days later. |
Clinical Trial Number | NCT00043576 |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | CRP |